PYC pyc therapeutics limited

0.00%

$1.20

Ann: PYC Nominates Fourth Clinical Drug Candidate in PMS Program, page-11

First 11 Last

Share
Profile

Follow
actionnaire

612 Posts.

322

17/12/24

17:15

Post #: 77091051
Share

Originally posted by hottod: ↑

Actually, the drug candidate PYC has chosen for PMS doesn’t use its peptide conjugate delivery technology.

Back in June 2023, PYC announced that it had optimised two different chemistries in parallel for the PMS asset, allowing optionality in the development path. One was the PPMO RNA chemistry that is used in PYC’s first three drug candidates and the other was 2′MOE RNA chemistry, a naked RNA drug chemistry which has already been clinically validated. It was explained that the 2’MOE chemistry already has an established path through non-clinical species studies to clinical validation and commercial success.

In June this year, PYC announced that it had been able to restore the deficient protein that causes PMS in the brain cells in which the disorder occurs (neurons), derived from a patient with PMS. While it was possible to achieve this using both chemistries, it was pointed out that the 2’MOE chemistry had already demonstrated clinical benefit in patients with disorders occurring in neurons.

Today it was announced that the clinical candidate for PMS has been finally decided. Pre-clinical studies have demonstrated that this candidate not only reaches the critical areas of the brain implicated in PMS but also corrects the underlying cause of PMS in neuron brain cells derived from PMS patients.

Rohan Hockings commented that “the read-through benefits from other clinically-validated drug candidates within this class in different diseases occurring in the same target cell and organ provide a clear path to the patient-impact that we are striving for.”

Earlier this year, Stoke Therapeutics announced successful Phase 1/2a results in Dravet syndrome, a monogenic neurodevelopmental disorder of haploisufficiency.* This drug candidate has since received Breakthrough Therapy Designation from the FDA. Stoke’s drug, which also targets neurons in the brain, uses a naked RNA chemistry.

Consequently, PYC has chosen to run with the 2’MOE chemistry for its PMS drug candidate.

Having an established pre-clinical and clinical pathway, successful clinical results in the same target cell and organ, and prior approval of drugs which use this chemistry, means there is the potential for less risk and a speedier path to commercialisation for PYC’s PMS asset.

In addition, it is my view that opting for an already proven chemistry makes pharma interest in partnering this asset from an earlier stage more likely, should PYC be interested in this option.

* https://hotcopper.com.au/threads/pyc-general-discussion.7711168/page-179?post_id=73080893

Expand

Sometimes I think I have it all sorted and I fully understand everything, and then along comes @hottod and teaches me I don't, which i am sincerely grateful for. It is reassuring to me that people such as you are here to help keep us informed about what we think we know when we actually don't know much at all..

Thank you Hottod I really appreciate your posts.

Happy Christmas everyone

Last edited by actionnaire: 17/12/24

PYC Price at posting: $1.45 Sentiment: Buy Disclosure: Held
39 Upvote

6 Great analysis

Reply

Top Stories

MEM

Many are concerned about global falling birthrates. This diverse stock has solutions

ASX Market Close: Bourse spins in circles as Israel-Iran conflict weighs | June 17, 2025

Almonty Industries – Now it is getting critical!

ASX Market Open: Shares down as Trump threatens 'real end' to Israel-Iran conflict | June 18

Listen: HotCopper Wire Podcast 013 - They changed the IPO rules (and that's a good thing)

First 11 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $1.20		Change 0.000(0.00%)		Mkt cap ! $699.9M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

Buyers (Bids)

No.	Vol.	Price($)
4	77891	$1.15

Sellers (Offers)

Price($)	Vol.	No.
$1.18	342	1

View Market Depth

No.	Vol.	Price($)
4	77891	1.150
1	50000	1.140
1	6756	1.130
1	889	1.125
3	9261	1.100

Price($)	Vol.	No.
1.180	342	1
1.200	20296	4
1.205	2270	1
1.210	6000	1
1.220	5596	2

Last trade - 09.30am 18/06/2025 (20 minute delay)

PYC (ASX) Chart

Day chart unavailable

Ann: PYC Nominates Fourth Clinical Drug Candidate in PMS Program, page-11

Many are concerned about global falling birthrates. This diverse stock has solutions

ASX Market Close: Bourse spins in circles as Israel-Iran conflict weighs | June 17, 2025

Almonty Industries – Now it is getting critical!

ASX Market Open: Shares down as Trump threatens 'real end' to Israel-Iran conflict | June 18

Listen: HotCopper Wire Podcast 013 - They changed the IPO rules (and that's a good thing)

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: PYC Nominates Fourth Clinical Drug Candidate in PMS Program, page-11

Top Stories

Many are concerned about global falling birthrates. This diverse stock has solutions

ASX Market Close: Bourse spins in circles as Israel-Iran conflict weighs | June 17, 2025

Almonty Industries – Now it is getting critical!

ASX Market Open: Shares down as Trump threatens 'real end' to Israel-Iran conflict | June 18

Listen: HotCopper Wire Podcast 013 - They changed the IPO rules (and that's a good thing)

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News